EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Hepatorenal Syndrome–Acute Kidney Injury in Liver Transplantation

Blanca Lizaola-Mayo, Hugo E Vargas

Clinical Gastroenterology and Hepatology · 2023

DOI: 10.1016/j.cgh.2023.06.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Blanca Lizaola-Mayo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Arizona, Liver Transplantation Center, Phoenix, Arizona. Hauptthemen laut MEDLINE: Hepatorenal Syndrome, Liver Transplantation, Acute Kidney Injury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatorenal syndrome (HRS) is a serious complication of cirrhosis. HRS nomenclature has recently changed to HRS-AKI (acute kidney injury). HRS is a complex response to chronic vasodilatory changes brought about by portal hypertension and exacerbated by inflammatory responses that portends poor prognosis to patients with cirrhosis. This syndrome is commonly seen in the setting of infections, particularly spontaneous bacterial peritonitis. Because of the frequency of renal injury in the patient with cirrhosis, HRS-AKI has to be considered high in the differential diagnosis of AKI. Discontinuation of potential triggering agents and elimination of pre-renal AKI, intrinsic renal disease, and structural uropathy as causes of injury are imperative on presentation. Volume expansion with albumin and vasoconstrictive drugs to counteract the underlying splanchnic vasodilation constitutes the most effective medical modality to manage this process. Although the most effective therapy is generally considered to be liver transplantation (LT), the logistic barriers of offering this life-saving therapy on time to all needing it is a major limitation. Terlipressin has been shown to reverse HRS-AKI in a significant proportion of those treated and consequently can lead to increased LT patient survival and freedom from renal replacement therapy. We will review the impact of HRS on the management of patients awaiting LT, present strategies to prevent this significant complication, and discuss major implications of recent therapeutic advances in the setting of LT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatorenal SyndromeLiver TransplantationAcute Kidney InjuryHumansKidneyLiver Cirrhosis

Stichwörter der Autor:innen

AscitesHRS-AKILiver TransplantNorepinephrineTerlipressinVasoconstrictors

Autor:innen und Institutionen

  • Mayo Clinic Arizona, Liver Transplantation Center, Phoenix, Arizona.
  • Mayo Clinic Arizona, Liver Transplantation Center, Phoenix, Arizona. Electronic address: vargas.hugo@mayo.edu.

Zitieren

APA

Lizaola-Mayo, B., & Vargas, H. E. (2023). Hepatorenal Syndrome–Acute Kidney Injury in Liver Transplantation. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.06.010

Vancouver

Lizaola-Mayo B, Vargas HE. Hepatorenal Syndrome–Acute Kidney Injury in Liver Transplantation. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.06.010

BibTeX
@article{LizaolaMayo2023,
  author = {Lizaola-Mayo, Blanca and Vargas, Hugo E},
  title = {Hepatorenal Syndrome–Acute Kidney Injury in Liver Transplantation},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1016/j.cgh.2023.06.010}
}
Kostenlos starten →